Skip to main content
logo
Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
4.607
-0.173 (-3.63%)
Oct 26, 2026, 11:10 AM EDT - Market open

Aligos Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
31.522.193.9515.5313.914.36
Revenue Growth
893.01%-44.59%-74.60%11.66%219.04%-
Gross Profit
-56.86-67.27-66.32-57.51-71.17-99.79
Operating Income
-78.99-87.99-89.15-87.4-97.58-128.32
Net Income
-75.96-24.19-131.21-87.68-96.05-128.33
Earnings Per Share
-7.31-2.45-20.94-34.20-56.25-80.50
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
30.3877.8456.94135.7125.83190.73
Total Debt
3.55.258.3811.1412.5714.46
Net Cash (Debt)
26.8872.5948.56124.57113.25176.28
Net Cash Growth
-76.84%49.48%-61.01%9.99%-35.75%-23.52%
Net Cash Per Share
2.587.347.7548.5966.31110.57

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-94.17-82.5-80.74-79-79.39-115.66
Capital Expenditures
-0.36-0.44-0.13-0.02-0.94-0.89
Free Cash Flow
-94.52-82.94-80.87-79.02-80.33-116.55
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
-250.63%-4024.93%-2259.92%-562.84%-701.66%-2943.82%
Pretax Margin
-230.81%-1092.36%-3317.62%-559.50%-689.87%-2940.79%
Profit Margin
-241.01%-1106.72%-3326.01%-564.62%-690.63%-2944.07%
FCF Margin
-299.90%-3794.15%-2050.01%-508.83%-577.64%-2673.87%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.9526.2437.483.202.93116.05